scout
|Videos|June 16, 2017

Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

In general, Hodgkin lymphoma is a very treatable disease, explains Schmitt. However, this may no longer apply to patients who are primarily refractory or have relapsed after standard treatment.

Schmitt investigated a preclinical study considering that a genetic or pharmacological approach to restore the B-cell phenotype of Hodgkin lymphoma cells could be therapeutic or could open the door for using treatment components such as antibodies or signaling inhibitors.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME